

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:) Examiner: To Be Assigned
)
Zarling et al.) Group Art Unit: To Be Assigned
)
Serial No. To Be Assigned)
)
Filed: November 20, 2001)
)
For: *In vivo Homologous Sequence*)
Targeting in Eukaryotic Cells)

"EXPRESS MAIL" MAILING LABEL

NUMBER EL735048161US

DATE OF DEPOSIT November 20, 2001

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO: UNITED STATES PATENT AND TRADEMARK OFFICE, BOX PATENT APPLICATION, P.O. BOX 2327, ARLINGTON, VA 22202.

TYPED NAME DARRYL KRINER

SIGNED 

United States Patent and Trademark Office
Box Patent
P.O. Box 2327
Arlington, VA 22202

PRELIMINARY AMENDMENT

Sir:

Prior to examination, please amend the above-identified application as follows:

In the Claims:

Please cancel claim 1, without prejudice or disclaimer.

Please add the following new claims:

49. A composition comprising:
- a) a plasmid comprising a target nucleic acid sequence;
 - c) at least two single-stranded targeting polynucleotides which are substantially complementary to each other, and which further comprise a homology clamp that substantially corresponds to or is substantially complementary to said target nucleic acid sequence; and
 - d) at least one recombinase.

Serial No.: To Be Assigned
Filed: September 20, 2001

50. The composition of claim 49 wherein said targeting polynucleotides are bound to said plasmid.

51. The composition of claim 49 wherein at least one of said targeting polynucleotides is biotinylated.

52. A method comprising contacting a plasmid comprising a target nucleic acid with a recombinase and at least two single-stranded targeting polynucleotides which are substantially complementary to each other, and which further comprise a homology clamp that substantially corresponds to or is substantially complementary to said plasmid target nucleic acid.

53. The method of claim 52 wherein said targeting polynucleotides are bound to said plasmid.

54. The method of claim 52 wherein at least one of said targeting polynucleotides is biotinylated.

REMARKS

Support for the above claims can be found on page 44 lines 26-29, page 63 lines 3-23, and page 69 lines 7-9 of the application.

The Commissioner is authorized to charge any additional fees including extension fees or other relief which may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our Order No. A-64580-5/RFT/NBC).

The applicants submit that the claims are supported by the specification and are in

Serial No.: To Be Assigned
Filed: September 20, 2001

condition for allowance. An early notification to that effect is earnestly solicited. Please direct any questions to the undersigned at (415) 781-1989.

Respectfully submitted,

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP



Richard F. Trecartin
Reg. No. 31,801

4 Embarcadero Center
Suite 3400
San Francisco, CA 94111
(415) 781-1989

1067988